Abstract
Alogliptin is a new drug for the treatment of Type 2 diabetes newly registered in the Czech Republic. It belongs to the gliptins family and its therapeutic effect is mediated through dipeptidyl peptidase-4 (DPP-4) inhibition, for which alogliptin has high selectivity.
The efficacy and safety (especially the low risk of hypoglycemia) was demonstrated in clinical trials, and alogliptin was overall well tolerated by patients. Cardiovascular safety was shown in the clinical trial EXANIME.
The basic recommended dose is 25 mg once a day. Alogliptin is registered as an additional combination treatment fo Type 2 diabetes with metformin, Thiazolidinediones, sulphonylurea or insulin, or for triple therapy with metformin and thiazolidinediones or insulin.
Alogliptin is also registered in two fixed combination pills with metformin or pioglitazone.